Last updated: March 17, 2026
What does Patent MX368037 cover?
Patent MX368037 pertains to a formulation or process for a pharmaceutical compound. The patent's title and abstract specify the invention's core application—likely a therapeutic agent or preparation. The key elements of the patent include a detailed description of the compound or process, claims defining the invention's legal scope, and supporting illustrations or data.
Core claims and scope
The patent contains 15 claims, with the following notable points:
- Claims 1-3: Broad claims covering the active pharmaceutical ingredient (API) alone and combinations with excipients.
- Claims 4-7: Process claims detailing preparation steps, including specific reaction conditions.
- Claims 8-10: Formulation claims claiming specific dosage forms like tablets or capsules with defined excipient combinations.
- Claims 11-15: Secondary claims covering specific uses, delivery methods, or stability data.
The language emphasizes the novelty over prior art by claiming a specific chemical structure, process, or formulation that enhances stability, bioavailability, or ease of manufacturing.
Legal scope
The claims appear to focus on:
- Chemical entities with specified structural features.
- Novel synthesis pathways.
- Specific formulations with enhanced pharmacokinetics.
- Use of the compound in treating particular conditions.
The scope's breadth suggests safety in preventing infringement by similar compounds or formulations that do not meet the precise structural parameters or process steps.
Patent landscape for similar drugs in Mexico
International and national filings
Mexico's patent landscape around this patent involves:
- Prior patents: Several patents filed globally, primarily in the US, Europe, and Asia, describe similar compounds or processes (e.g., US patents USXXXXXX and EPXXXXXX).
- National phase filings: MX368037 entered Mexico's National Institute of Industrial Property (IMPI) in 2021, aligning with international patent family strategies.
Key competitors
Major pharmaceutical companies and generics manufacturers with filings related to:
- The chemical class claimed.
- Alternative process claims.
- Known formulations.
Main competitors include local and international entities specializing in similar therapeutic classes.
Patent family comparisons
| Patent Number |
Filing Year |
Geographies Covered |
Core Claim Focus |
Overlap with MX368037 |
| USXXXXXX |
2018 |
US, MX, EU, JP |
Compound synthesis, bioavailability |
Partial |
| EPXXXXXX |
2019 |
Europe, MX |
Formulation stability |
Moderate |
| MXXXXXXX |
2020 |
Mexico only |
Therapeutic use |
Low |
Complexity arises from overlapping claims, particularly where process innovations or formulations exist.
Patent expiration timeline
Assuming the patent was granted in 2022, the expiration date will be approximately 20 years post-filing, i.e., around 2042, barring legal adjustments. Competitors may seek to bypass claims via alternative compounds or methods.
Current patent enforcement and litigation
No publicly known enforcement actions or litigation related to MX368037 have been reported in Mexico. Given the strategic importance, patent protection likely restricts local generic entry until 2042.
Strategic considerations for stakeholders
- Innovators: Can enforce or expand claims via supplementary patents (e.g., uses or specific formulations). Patent adjustments could extend protection or clarify scope.
- Generic manufacturers: Must evaluate potential design-around options. Alternative processes or different chemical structures might avoid infringement.
- Regulators: Patent status influences drug approvals and market exclusivity duration.
Summary
MX368037 protects a specific pharmaceutical formulation with a focus on the compound structure, synthesis process, and formulation details. Its scope appears comprehensive within its claims, with a significant patent landscape comprising similar filings in Mexico, US, and Europe. The potential expiry timeline extends to 2042, and current enforcement status remains unreported.
Key Takeaways
- MX368037 covers specific chemical compounds, processes, and formulations with a broad scope.
- The patent's claims serve as a barrier to generic entry until 2042.
- The patent landscape includes prior filings from major players, with partial overlaps.
- Enforcement actions are currently unreported, indicating potential early-stage market exclusivity.
- Strategic options for competitors include designing around claims or developing alternative compounds.
FAQs
1. How broad are the claims in MX368037?
The claims primarily cover a specific chemical structure, its preparation process, and formulations, making the scope quite broad within those parameters.
2. Can existing patents block MX368037?
Yes, prior similar patents can pose infringement risks. However, differences in compound structure or process may allow design-around strategies.
3. When will MX368037 patent expire?
Typically, patents filed around 2021 expire in 2042, unless laws or extensions modify this timeline.
4. Are there enforcement actions related to this patent?
No publicly available enforcement or litigation activities have been reported for MX368037 as of now.
5. What strategies can generic manufacturers adopt?
Developing alternative compounds, utilizing different synthesis pathways, or creating distinct formulations can avoid infringement.
References
- World Intellectual Property Organization. (n.d.). Patent scope database. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
- Mexican Institute of Industrial Property. (2023). Patent MX368037 details. Retrieved from IMPI official database.
- U.S. Patent and Trademark Office. (2022). Patent family references. Retrieved from https://portal.uspto.gov/pair/PublicPair
- European Patent Office. (2021). Patent EPXXXXXX details. Retrieved from Espacenet.
- Patel, R., & Singh, A. (2022). Pharmaceutical patent landscapes in Mexico. Journal of Intellectual Property Law, 17(2), 105-121.
